: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2018 Financial Results Utica, New York

CONMED Corporation Announces

Third Quarter 2018 Financial Results

Utica, New York, November 1,

2018 --- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the third quarter ended September 30, 2018.

Third Quarter 2018 Highlights

"We are pleased with our

strong global performance in the third quarter, which reflects continued execution against our strategic plans," commented

Curt R. Hartman, CONMED's President and Chief Executive Officer. "We believe we are well-positioned to continue to

deliver above-market revenue growth and attractive returns to our shareholders."

For the quarter ended September

30, 2018, domestic sales, which represented 53.2% of total revenue, increased 9.4% on a reported basis, with growth in both General

Surgery and Orthopedics. On January 1, 2018, the Company began adjusting its sales for administrative fees by recording these fees

as a reduction of revenue under ASU No. 2014-09, Revenue from Contracts with Customers ("ASC 606"). For the third quarter

of 2017, these administrative fees totaled $2.0 million. As a result, on an adjusted(1) basis, domestic sales increased

11.7% year over year.

International sales, which represented

46.8% of total revenue, increased 3.2% compared to the third quarter of 2017 on a reported basis. Foreign currency exchange rates,

including the effects of the FX hedging program, had a negative impact of $1.2 million on third quarter sales. In constant currency,

international sales increased 4.5% versus the prior-year period.

For the quarter ended September

30, 2018, reported net income totaled $5.8 million, compared to reported net income of $7.2 million a year ago. Reported diluted

net earnings per share were $0.20 in the quarter, compared to reported diluted earnings per share of $0.26 in the prior-year period.

Reported net income for 2017 included restructuring costs, business acquisition costs, and legal costs. Reported net income for

the third quarter of 2018 includes a $2.1 million impairment charge, net of tax, primarily related to an in-process research and

development asset, net of release of accrued contingent consideration, and a $0.8 million charge, net of tax, related to a vacant

leased facility, both of which are associated with prior acquisitions. The effect of each of these items on reported net income

and reported diluted net earnings per share appears in the reconciliation of GAAP to non-GAAP measures below.

The Company excludes the costs of

special items, including acquisitions, restructurings, legal matters, gains on the sale of assets, debt refinancings, impairment

charges, amortization of intangible assets, net of tax, as well as adjustments to the December 2017 tax balances and provisional

income tax effects of the 2017 Tax Cuts and Jobs Act, from its adjusted diluted net earnings per share. Excluding the impact of

these items, adjusted net income(4) of $13.3 million increased 13.0% year over year, and adjusted diluted net earnings

per share(3) of $0.46 increased 9.5% year over year. The increase in adjusted net income(4) resulted primarily

from higher sales and a lower effective tax rate.

Based on current business trends,

CONMED is raising the low end of its previously issued constant-currency sales guidance. The Company now expects full-year 2018

constant-currency and as adjusted(1) sales growth in the range of 6.5% to 7%, compared to the previous range of 6% to

7%. Based on recent exchange rates, the positive impact to 2018 sales from foreign exchange is anticipated to be between 0 and

50 basis points, which is consistent with the Company's previously issued guidance.

The Company continues to forecast

full-year 2018 adjusted diluted net earnings per share in the range of $2.15 to $2.20. This represents growth over 2017 of approximately

14% to 16%. The adjusted diluted net earnings per share estimates for 2018 exclude the cost of special items, including acquisition

costs, restructuring costs, impairment charges, and adjustments to the December 2017 tax balances and provisional income tax effects

of the 2017 Tax Cuts and Jobs Act, which are estimated in the range of $4 to $5 million, net of tax, and amortization of intangible

assets, which is estimated in the range of $16 to $18 million, net of tax.

Supplemental Financial Disclosures

(1) Adjusted net sales

growth is measured in constant currency and is adjusted for administrative fees that the Company began recording as a reduction

of revenue under ASC 606, Revenue from Contracts with Customers, effective January 1, 2018.

(2) A reconciliation

of reported gross margin to adjusted gross margin, a non-GAAP financial measure, appears below.

(3) A reconciliation

of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

(4) A reconciliation

of reported net income to adjusted net income, a non-GAAP financial measure, appears below.

The Company's management will

host a conference call today at 4:30 p.m. ET to discuss its third quarter 2018 results.

To participate in the conference

call, dial 844-889-7792 (domestic) or 661-378-9936 (international)

and refer to the passcode 3386328.

This conference call will also

be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com.

The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also

be available from 7:30 p.m. ET on Thursday, November 1, 2018, until 6:30 p.m. ET on Thursday, November 15, 2018. To hear this recording,

dial 855-859-2056 (domestic) or 404-537-3406 (international) and enter the passcode 3386328.

About CONMED Corporation

CONMED is a medical technology

company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used

by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

CONMED has a direct selling presence in 19 countries, and international sales constitute approximately 50% of the Company's

total sales. Headquartered in Utica, New York, the Company employs approximately 3,100 people. For more information, visit www.conmed.com.

Forward-Looking Statements

and today's conference call may contain forward-looking statements based on certain assumptions and contingencies that involve

risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in

the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions,

factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are

not limited to, the risk factors discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017,

and listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q. Any and all

forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995

and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements

made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections

as expressed in the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation

of GAAP to Non-GAAP Financial Measures

supplements the reporting of its financial information determined under accounting principles generally accepted in the United

States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency and as adjusted

for ASC 606; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted

research and development expense; adjusted operating income; adjusted income tax expense; adjusted effective income tax rate; adjusted

net income and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful

information to assist investors and shareholders in understanding its financial results and assessing its prospects for future

performance. Management believes percentage sales growth as adjusted for ASC 606 and in constant currency and the other adjusted

measures described above are important indicators of its operations because they exclude items that may not be indicative of, or

are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company's underlying business.

Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company's

cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future

business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial

an "adjusted" basis is a non-GAAP measure that presents net sales in "constant currency" and adjusts for the

adoption impact of ASC 606. The Company analyzes net sales on a constant currency basis to better measure the comparability of